Platelet aggregation profile as a marker of hydroxyurea bioavailability through nitric oxide generation in chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 47, Issue 4, 2006, Pages 741-746

  Lahiri, Prabir ^a   Chaudhuri, Utpal ^a   Chattopadhyay, Arnab ^a   Dasgupta, Anjan K R ^b  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b UNIVERSITY OF CALCUTTA   (India)

Author keywords

CML; Hydroxyurea; NO; ODQ; Platelet aggregation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; GUANYLATE CYCLASE; HYDROXYUREA; NITRIC OXIDE;

ADULT; ARTICLE; CELL SUSPENSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADULT; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; CYCLIC GMP; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; OXADIAZOLES; PLATELET AGGREGATION; QUINOXALINES; TIME FACTORS;

EID: 33646777480     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500375854     Document Type: Article

References (19)

1. King, S. (2003) The nitric oxide producing reactions of hydroxyurea Curr Med Chem, 10, pp. 437-452.
2. Boyd, A and Nelder, K. (1991) Hydroxyurea therapy J Am Acad Dermatol, 25, pp. 518-524.
3. Fishbein, W and Carbone, P. (1963) Hydroxyurea: Mechanism of action Science, 142, pp. 1069-1070.
4. Nyholm, S and Thelander, L and Grasland, A. (1993) Reduction and loss of iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea Biochemistry, 32, pp. 11569-11574.
5. Garcia-Manero, G and Faderi, S and O'Brien, S and Cortes, J and Talpaz, M and Kantarjian, H. (2003) Chronic myelogenous leukemia: A review and update of therapeutic strategies Cancer, 96, pp. 437-457.
6. Wang, P and Xian, M and Tang, X and Wu, X and Wen, Z and Cai, T et al. (2002) Nitric oxide donors: Chemical activities and biological applications Chem Rev, 102, pp. 1034-1091.
7. King, S. (2004) Nitric oxide production from hydroxyurea Free Radic Biol Med, 37, pp. 737-744.
8. Huang, J and Sommers, E and Kim-Shapiro, D and King, S. (2002) Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea J Am Chem Soc, 124, pp. 3473-3480.
9. Jiang, J and Jordan, S and Barr, D and Gunther, M and Meada, H and Mason, R. (1997) In vivo production of nitric oxide in rats after administration of Hydroxyurea Mol Pharmacol, 52, pp. 1081-1086.
10. Craven, P and DeRubertis, F. (1978) Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation J Biol Chem, 253, pp. 8433-8443.
11. Mellion, B and Ignarro, L and Ohlstein, E and Pontecorvo, E and Hyman, A and Kadowitz, P. (1981) Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators Blood, 57, pp. 946-955.
12. Radomski, M and Palmer, R and Moncada, S. (1987) The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide Br J Pharmacol, 92, pp. 639-646.
13. Severina, I. (1994) Soluble platelet guanylate cyclase: Significance of heme in regulating enzymatic activity and the role of the enzyme in platelet aggregation Biokhimiia, 59, pp. 325-339.
14. Moro, M and Russel, R and Cellek, S and Lizasoain, I and Su, Y and Darley-Usmar, V et al. (1996) cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase Proc Natl Acad Sci USA, 93, pp. 1480-1485.
15. Eigenthaler, M and Ullrich, H and Geiger, J and Horstrup, K and Honig-Liedl, P and Wiebecken, D et al. (1993) Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia J Biol Chem, 268, pp. 13521-13526.
16. 1 H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one Mol Pharmacol, 48, pp. 184-188.
17. Conran, N and Oresco-Santos, C and Acosta, H and Fattori, A and Saad, S and Costa, F. (2004) Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients Br J Haematol, 124, pp. 547-554.
18. Cokic, V and Smith, R and Beleslin-Cokic, B and Njoroge, J and Miller, J and Gladwin, M et al. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase J Clin Invest, 111, pp. 231-239.
19. Rodriguez, G and Kuhn, J and Weiss, G and Hilsenbeck, S and Eckardt, J and Thurman, A et al. (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea Blood, 91, pp. 1533-1541.